News
Market and company headlines
MRNAAll
Loading
09:00Today2 Stories
Moderna shares slip as William Blair cuts rating on valuation after rally
Investing.com -- Moderna Inc (NASDAQ:MRNA) slid 3% in premarket trading after William Blair downgraded the biotechnology company to Market Perform from Outperform, citing valuation constraints following a meteoric run. The downgrade follows a staggering 545% year-to-date rally, driven by a near-250% surge since August after encouraging Phase 3 INTERPATH-001 data for its personalized cancer vaccine candidate.
Moderna Has Its Doubters. CEO Bancel Plans to Answer With a Cancer Shot.
Moderna CEO Stéphane Bancel says the biotech’s competitive edge stems from its mRNA platform, likening it to software in Big Tech.
04:00-06:00Today2 Stories
William Blair Takes a Shot at Moderna Stock: Downgrade to Market Perform After a 545% Run
Moderna shares are trading lower Tuesday after William Blair downgraded the stock to Market Perform on Monday, citing valuation concerns.
William Blair Downgrades Moderna to Market Perform
William Blair analyst Myles Minter downgrades Moderna (NASDAQ:MRNA) from Outperform to Market Perform.
18:00-21:00Yesterday2 Stories
Moderna (MRNA) Gets Phase 3 Melanoma Vaccine Validation At ESMO And NEJM
Moderna (NasdaqGS:MRNA) and Merck reported detailed Phase 3 data for their individualized mRNA melanoma vaccine plus KEYTRUDA, intismeran, at ESMO 2026. The Phase 3 trial showed a significant reduction in disease recurrence and distant metastasis in melanoma patients receiving the combination regimen. The intismeran results have been accepted for publication in The New England Journal of Medicine, adding peer reviewed validation for the program. The mRNA melanoma vaccine and KEYTRUDA Phase 3...
Moderna CEO Says Its Cancer Vaccine Isn’t a Disappointment, It’s a Blockbuster
Moderna’s stock tanked Thursday following a data leak for the drugmaker’s cancer-vaccine candidate, which is co-developed with Merck.
15:00Yesterday3 Stories
Moderna Sinks Another 8% Even as Lead Investigator Calls Melanoma Vaccine Data “Transformational”
Key TakeawaysModerna shares fell another 8% this morning. On Saturday it and its partner Merck presented full Phase 3 data showing their personalized melanoma vaccine cut the risk of recurrence or death by 42%.
Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy - Slideshow
2026-10-26. The following slide deck was published by Moderna, Inc.
10:00Yesterday2 Stories
Moderna’s Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show.
Amgen showcases “excellent” data for its small-cell lung cancer treatment following leaked results for Moderna and Merck’s intismeran autogene.
Moderna Recovers From 10% Dive, But Muted Expectations Haunt Cancer Vaccine
Moderna stock yo-yoed Monday on more muted expectations for its Merck-partnered cancer vaccine, INT.
07:00Yesterday1 Story
09:00Oct 251 Story
14:00-19:00Oct 242 Stories
Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial
Moderna (NASDAQ:MRNA) presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck’s pembrolizumab for patients with resected high-risk melanoma. The INTerpath-001 trial met its primary endpoint of relapse-free survival and a key secondary endpoint of di
Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy Transcript
Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy October 24, 2026 1:00 PM EDTCompany ParticipantsDavid...
10:00Oct 241 Story
10:00-12:00Oct 234 Stories
MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress
Moderna falls despite positive phase III cancer therapy data showing reduced melanoma recurrence and metastasis risks, as investors weigh elevated expectations.
Moderna’s Stock Just Stumbled. Is It a Buy on the Dip?
The stock fell 17% in one trading session.
00:00Oct 232 Stories
Moderna Slides Up to 25% as Cancer Vaccine Meets Sky-High Expectations
Moderna fell up to 25% despite a cancer vaccine that cut melanoma recurrence or death risk 42%, as expectations ran high.
After Moderna's 672% Climb, The Story Has Changed
Moderna spent much of 2025 caught between bullish hopes for mRNA expansion and bearish warnings about shrinking COVID demand and tighter pricing. For Moderna shareholders, the return over the past year was 671.9%, including dividends. If you had been weighing those sharply different analyst views in October 2025, how would you have judged the odds that such an extreme outcome could follow from the business that was on record then? The move put Moderna in the middle of this trade. Scan 36...
21:00-23:00Oct 222 Stories
Why Moderna (MRNA) stock is trading lower today
Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 22.7% in the afternoon session after the company's partial Phase 3 data for its personalized cancer vaccine leaked ahead of a planned presentation this weekend, and the stock sold off hard even though the results themselves look positive. According to CNBC, shares fell as much as 25% after an early look at the vaccine Moderna is developing with Merck, intismeran autogene, showed up online before it was supposed to be presented at the Eur
MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings
Mizuho analyst Jared Holz said the vaccine data weren’t bad, but Wall Street’s expectations were too high.
17:00-21:00Oct 222 Stories
Moderna stock’s 17% slump was a ‘sell the news’ event, analyst says
Moderna shares tumbled after leaked cancer vaccine trial data showed promising results for its treatment developed with Merck.
Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports
Personalized cancer vaccine material allegedly circulated online ahead of formal Phase 3 results, today, Oct. 22, 2026.
16:00Oct 223 Stories
Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data
Moderna shares are taking a hit after the leak of highly anticipated details about the company’s vaccine for the skin cancer melanoma.
MRNA Stock Plunges 18% After Leaked Melanoma Vaccine Data Misses High Hopes
Investors were awaiting full data from the late-stage trial of intismeran autogene plus Merck’s Keytruda at the European Society for Medical Oncology Congress on October 24.
15:00Oct 222 Stories
Details of Moderna's Breakthrough Cancer Vaccine Got Leaked. Its Stock is Plunging.
The stock fell up to 25% even though the data that was leaked was positive in relation to Wall Street's expectations.
Moderna stock crashes as leaked melanoma data threatens its record August rally
Leaked results from Moderna's melanoma vaccine trial have the stock challenging its worst day ever, while the rest of healthcare rallies.
14:00Oct 222 Stories
Moderna Stock Plummets 25% After Cancer-Vaccine Data Leak
Moderna shares tumbled as reported results for its cancer vaccine with Merck circulated ahead of a planned conference presentation.
Moderna Stock Plunges as Apparent Leak Reveals Phase 3 Melanoma Vaccine Data
Key TakeawaysModerna Inc. (NASDAQ:MRNA) sank as much as roughly 25% intraday after apparent Phase 3 results for its personalized melanoma vaccine surfaced online ahead of an embargoed medical-conference presentation.
01:00-14:00Oct 222 Stories
Moderna shares plunge on apparent cancer vaccine data leak
Investing.com -- Moderna shares plunged more than 25% on Thursday, while Merck fell over 3%, after what appeared to be an early release of closely watched clinical trial results for the companies’ experimental cancer vaccine.
Is Moderna (MRNA) Fully Valued Following Its NASDAQ 100 Inclusion?
Moderna (MRNA) has just been added to the NASDAQ-100 Index. This move places the biotech company alongside some of the largest non-financial companies on the exchange and is drawing fresh attention to its shares. Recent trading has been strong, with Moderna’s share price delivering a 42.14% 1 month gain and a very large year to date share price return. The 1 year total shareholder return is also very large, pointing to powerful momentum following this NASDAQ-100 inclusion. See how Moderna’s...
00:00Oct 221 Story
08:00-17:00Oct 212 Stories
Moderna (MRNA) Rises Higher Than Market: Key Facts
The latest trading day saw Moderna (MRNA) settling at $245.81, representing a +1.54% change from its previous close.
Moderna's Respiratory Portfolio Expands: Can It Reduce COVID Reliance?
MRNA expands beyond COVID-19 with new RSV, flu and combination vaccines, but fierce competition could challenge its efforts to diversify revenue.
04:00Oct 211 Story
06:00Oct 201 Story
06:00-19:00Oct 192 Stories
Moderna, Progyny, Azenta, Oscar Health, and agilon health Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in rising expectations that midterm election outcomes could reverse recent federal spending cuts.
What's Going On With Moderna Stock Monday?
Moderna shares are trading higher Monday ahead of detailed Phase 3 melanoma data due Saturday and after BofA raised its price target.
09:00-00:00Oct 182 Stories
Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In
Humacyte, Vera, Maze and Climb Bio will present dialysis-access and kidney-disease findings at ASN Kidney Week.
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.
It was a head-turning headline. Here's why the market was buzzing.
00:00-13:00Oct 172 Stories
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.
Phase 3 Cancer Vaccine Success Could Change The Case For Moderna Stock
Moderna was recently added to the Nasdaq-100 Index after positive Phase 3 data for its personalized cancer vaccine with Merck highlighted a pivot toward oncology beyond COVID-focused products. The late-stage success of intismeran positions Moderna's mRNA platform as a potential multi-product franchise across cancer and other conditions rather than a single-therapy story. Next, the focus turns to how this cancer vaccine progress could reshape Moderna's broader investment narrative around...
16:00Oct 162 Stories
Moderna Stock Slumps, but It’s Too Early to Panic
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields restricted market appetite for risk.
12:00-16:00Oct 162 Stories
Moderna and Novavax Stocks Slump as Biotech’s Rally Takes a Breather
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Vaccine stocks are cracking under intense selling pressure, and one small developer with no control over its own commercial fate is bearing the worst of it. Whether its big-pharma partner can change that story is the question every shareholder now faces.
10:00-12:00Oct 163 Stories
Moderna stock sinks as Wall Street turns cautious following blistering rally
Moderna sank as Wall Street grew more cautious on the company's valuation after a massive rally this year.
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Moderna stock is shedding 10% after a blistering cancer vaccine run, and the question now is whether profit takers know something the bulls don't ahead of a critical trial readout later this month.
09:00Oct 161 Story
20:00Oct 92 Stories
BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push
National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times reported on Friday.
Why Moderna Stock Surged Today
The biotech could play a significant role in a national effort to combat cancer.
16:00Oct 92 Stories
MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push
Moderna shares on Friday were driven by multiple catalysts, including a Nasdaq-100 entry, a New York Times report on a planned NIH-backed cancer-vaccine push and a price target hike.
Everest Medicines (SEHK:1952) Gains Fresh MRNA Firepower As Undervalued View Holds
Why Everest Medicines Stock Is Back On Investors’ Radar Everest Medicines (SEHK:1952) just added two experienced mRNA cancer vaccine scientists, Lakshmi Srinivasan, PhD, and Brandon Coder, PhD, to help advance its AI+mRNA platform and upcoming clinical programs. Those hires come at a time when Everest Medicines’ share price has been volatile, with a 90 day share price return of 7.64%, a year to date share price return down 21.9%, and a 1 year total shareholder return down 44.36%. This points...